Drug lookup | Fillwise

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

All products: not a benefit

Other products in the same Health Canada class (A02B) — coverage varies; not interchangeable

Cimetidine (Cimetidine): general benefit, Not a benefit
Famotidine (Pepcid): general benefit, Not a benefit
Misoprostol (Cytotec): general benefit, Not a benefit
Nizatidine (Axid): general benefit
Pantoprazole (Tecta): general benefit
Rabeprazole (Pariet): general benefit

7 more in the class list below

Hp-PAC · DIN 02238525 · 30mg & 500mg & 500mg · tablet/capsule Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-03-08 — choose a marketed DIN from the same-category list.Discontinued 2021-03-08 · checked 2026-09-19

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-03-08 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-03-08 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 306, 307

Reason for Use code 306 For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a course of up to 14 days. Maximum duration: 14 days. Coverage limit: LU Authorization Period: 1 year Reason for Use code 307 For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a course of up to 14 days. Maximum duration: 14 days (after a four-week period has elapsed since the end of the previous treatment) Coverage limit: Retreatment decisions should be based upon positive symptoms and positive endoscopy or positive urea breath test. Retreatment should not be based on a positive serology test, as serology tests may remain positive indefinitely. An alternative antibiotic regimen is recommended when initial therapy fails due to concerns of antimicrobial resistance. Coverage limit: LU Authorization Period: 1 year

1 brand, same coverage

Hp-PAC · DIN 02238525 Manufacturer: Takeda Pharmaceuticals America Inc.; listing date 1999-04-15 Health Canada: Cancelled post market since 2021-03-08 · brand HP-PAC · ATC A02BD07 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN · form Capsule, Capsule (delayed-release), Kit, Tablet · route Oral · ingredients LANSOPRAZOLE 30 MG/CAP, AMOXICILLIN 500 MG/CAP, CLARITHROMYCIN 500 MG/TAB · company Takeda pharmaceuticals america inc · schedule Prescription

Check this DIN again · Health Canada product record

Hp-PAC: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61948 · Verify on the e-Formulary ↗ (DIN 02238525)

Source record

DIN 02238525: Hp-PAC Raw flags: notABenefit=Y, sec3=Y Item: 564000091; group id 681; item number 1698; lccId 00104; manufacturer id TPA Source form: Tab/Cap Pk; strength: 30mg & 500mg & 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238525 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61948

Interchangeable products

AA-LansoprazoleAmoxicillinClarithromycin · DIN 02470780 · $67.9100

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2021-03-08 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more

Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS The components of the AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN [lansoprazole delayed-release capsules, in combination with clarithromycin tablets plus amoxicillin capsules as triple therapy], are indicated for: ● the treatment of patients with Helicobacter pylori (H. pylori) infection and active duodenal ulcer disease. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see 14.1 Clinical Trials by Indication and 4 DOSAGE AND ADMINISTRATION). In patients with a recent history of duodenal ulcers who are H. pylori positive, eradication therapy may reduce the rate of recurrence of duodenal ulcers. The optimal timing for eradication therapy for such patients remains to be determined. In patients who fail a therapy combination containing clarithromycin, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, an alternative therapy combination is recommended. Resistance to amoxicillin has not been demonstrated in clinical studies with lansoprazole delayed-release capsules and amoxicillin. Table 1 summarizes the eradication rates for th… https://pdf.hres.ca/dpd_pm/00077480.PDF PM date: OCT 18, 2024 Source product: AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN; DIN 02470780; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Hp-PAC: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026